Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b + /CCR3 − /Gr-1 − cells cytotoxic against the tumor cells

doi: 10.1007/s00262-009-0708-5

Figure Lengend Snippet: Inhibition of tumor growth by specific elimination of macrophages infiltrating into the tumors. For elimination of macrophages infiltrating into the tumors, undiluted DMDP- or PBS-liposome solution (0.2 ml/mouse) was i.d. injected into four spots in the dorsal region of the skin to surround the tumor on days 0 and 2 after tumor (5 × 105 cells/mouse) injection. a Histological features of skin on day 6. Arrow represents tumor injection site. Arrow head represents liposome injection site. Scale bar = 250 μm. b 3LL lung cancer cells; c B16 melanoma cells; d KLN205 squamous carcinoma cells. Open circles indicate PBS-liposomes; closed circles indicate DMDP-liposomes. Each value represents the mean ± SD of five mice. The difference between sample (DMDP-liposomes) and control (PBS-liposomes) is significant (*P < 0.05; **P < 0.02; ***P < 0.01; ****P < 0.005; *****P < 0.002; ******P < 0.001) according to Student’s t-test. n.s. not significant

Article Snippet: 3LL cells (Lewis lung carcinoma cell line of C57BL/6 origin), B16 cells (melanoma cell line of C57BL/6 origin), and KLN205 cells (squamous cell carcinoma cell line of DBA/2 origin) were purchased from American Type Culture Collection (Manassas, VA, USA).

Techniques: Inhibition, Injection, Liposomes, Control

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b + /CCR3 − /Gr-1 − cells cytotoxic against the tumor cells

doi: 10.1007/s00262-009-0708-5

Figure Lengend Snippet: Growth of i.d. transplanted tumor cells (each 5 × 105 cells/mouse). B16 melanoma cells (C57BL/6 origin), KLN205 squamous cell carcinoma cells (DBA/2 origin) or 3LL Lewis lung cancer cells (C57BL/6 origin) were transplanted into the dorsal dermis of syngeneic mice. At appropriate intervals after tumor transplantation, the size of the tumor was assessed. Each value for the tumor size represents the mean ± SD of four mice. Open circles indicate 3LL cells; open triangles indicate B16 cells; open squares indicate KLN205 cells

Article Snippet: 3LL cells (Lewis lung carcinoma cell line of C57BL/6 origin), B16 cells (melanoma cell line of C57BL/6 origin), and KLN205 cells (squamous cell carcinoma cell line of DBA/2 origin) were purchased from American Type Culture Collection (Manassas, VA, USA).

Techniques: Transplantation Assay

Journal: Cancer research

Article Title: SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines

doi: 10.1158/0008-5472.CAN-14-1768-A

Figure Lengend Snippet: Vaccination with the SA-4-1BBL/MPL adjuvant system induces strong anti-tumor CD8+ T cell effector responses that correlate with vaccine efficacy. Long-term (> 90 days) surviving mice were boosted with the same vaccine formulations used for primary immunization as indicated. Lymph node cells were harvested 7 days later and assessed for E749-57 peptide-specific CD8+ T cells expressing intracellular IFN-γ mono (A), IFN-γTNF-α double (B), and IFN-γTNF-αIL-2 triple (C) cytokines. Lymph node cells from naïve mice stimulated with E7 peptide were used as background control with minimal to undetectable cytokine response (0-1% cells). Data is expressed as percentage of total CD8+ T cells (D), Splenocytes from mice from above groups were stimulated with E749-57 peptide and IL-2 for 5 days and used as effectors against TC-1 tumor targets. 3LL tumor cells were used as irrelevant targets. Data shown are the mean ± SEM of 3-4 mice per group and representative of two independent experiments. * P≤ 0.05, *** P≤ 0.001, ns> 0.05.

Article Snippet: TC-1 and 3LL cell lines were purchased from ATCC and not authenticated.

Techniques: Adjuvant, Expressing, Control

Journal: Cancer research

Article Title: SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines

doi: 10.1158/0008-5472.CAN-14-1768-A

Figure Lengend Snippet: Vaccination with the SA-4-1BBL/MPL adjuvant system generates potent therapeutic response in the 3LL lung metastasis model. Mice (n = 4-5/group) were challenged with 2×105 3LL cells by i.v. tail injection and vaccinated once s.c. on day 6 post-tumor challenge with SVN (50 μg) alone or with SA-4-1BBL (25 μg), MPL (25 μg), or a combination of both agents (25 μg/agent). (A), Lungs were harvested 27 days post tumor challenge and assessed for tumor growth by weight and macroscopic presence of tumor nodules. (B), Intracellular IFN-γ response of CD8+ T cells was assessed after PMA and ionomycin stimulation of lymphocytes harvested from mice in (A). * P≤ 0.05, *** P≤ 0.001, ns> 0.05.

Article Snippet: TC-1 and 3LL cell lines were purchased from ATCC and not authenticated.

Techniques: Adjuvant, Clinical Proteomics, Injection

Journal: Cancer research

Article Title: SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines

doi: 10.1158/0008-5472.CAN-14-1768-A

Figure Lengend Snippet: Vaccination with the SA-4-1BBL/MPL adjuvant system does not promote chronic autoimmunity or acute toxicity. Sera were harvested from mice from Fig. 1(A) and Fig. 5(A) at the experimental endpoints and tested for the presence of autoantibodies against ssDNA in TC-1 (A) and 3LL (B) tumor models. Serum pooled from a minimum of 3 naïve and 3 lupus mice were used as negative and positive controls, respectively. Acute toxicity was assessed in naïve C57BL/6 mice treated once with SA-4-1BBL/MPL adjuvant system and euthanized after 18 hrs for (C), vaccine-induced organ damage by measuring serum levels of ALT and AST for liver; BUN and CREA for renal function. (D), H&E staining of liver tissues, showing lack of pathology.

Article Snippet: TC-1 and 3LL cell lines were purchased from ATCC and not authenticated.

Techniques: Adjuvant, Staining

Journal: Journal of Translational Medicine

Article Title: Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

doi: 10.1186/1479-5876-4-24

Figure Lengend Snippet: Tumor-specific protective immunity in long-term survivor mice. IL-21 + IL-2 treated mice that survived disease free for 150 days were rechallenged with B16F10 (5 × 10 5 ) or 3LL(5 × 10 4 ) tumor cells. All 3LL challenged mice (4/4) exhibited mean tumor growth to ≥ 200 mm 2 by day 32; all B16F10 challenged mice (5/5) were protected. Naïve mice challenged with the same B16F10 (5/5) or 3LL (5/5) tumor cells had rapid mean tumor growth to ≥ 200 mm 2 by day 25.

Article Snippet: The B16 F10 melanoma and 3LL (Lewis Lung) cell lines were obtained from ATCC.

Techniques:

Journal: British Journal of Cancer

Article Title: A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors

doi: 10.1038/sj.bjc.6600667

Figure Lengend Snippet: Inhibitory effect of KIN-841 on proliferation of BPAE cells and 3LL cells under normoxia. Cells were treated for 48 h with KIN-841 at the various concentrations indicated. a P <0.05 vs controls; b P <0.05 vs normoxia.

Article Snippet: Lewis lung carcinoma and cultured Lewis lung carcinoma (3LL) cells were from Dr T Sakurai (Keio University, Tokyo, Japan).

Techniques:

Journal: British Journal of Cancer

Article Title: A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors

doi: 10.1038/sj.bjc.6600667

Figure Lengend Snippet: Inhibitory effect of KIN-841 on proliferation of 3LL cells under hypoxia. Cells were treated for 48 h with KIN-841 at the various concentrations indicated under normoxia or hypoxia. a P <0.05 vs controls; b P <0.01 vs controls; c P <0.05 vs normoxia.

Article Snippet: Lewis lung carcinoma and cultured Lewis lung carcinoma (3LL) cells were from Dr T Sakurai (Keio University, Tokyo, Japan).

Techniques:

Journal: British Journal of Cancer

Article Title: A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors

doi: 10.1038/sj.bjc.6600667

Figure Lengend Snippet: Inhibitory effect of KIN-841 on the production of angiogenic factor in 3LL cells under hypoxia. ( A ) Effect of 3LL cell-CM treated with KIN-841 at the various concentrations indicated under normoxia or hypoxia on [ 3 H]thymidine incorporation in BPAE cells. a P <0.01 vs normoxia controls; b P <0.01 vs hypoxia controls. ( B ) Effects of KIN-841 and anti-VEGF antibody on stimulation of [ 3 H]thymidine incorporation in BPAE cells by 3LL cell-CM incubated under normoxia or hypoxia. a P <0.05 vs normoxia controls; b P <0.05 vs normoxia controls; c P <0.01 vs hypoxia controls. ( C ) VEGF concentration in 3LL cell-CM treated with KIN-841 at the various concentrations indicated under normoxia or hypoxia. a P <0.05 vs normoxia controls; b P <0.05 vs hypoxia controls; c P <0.01 vs hypoxia controls.

Article Snippet: Lewis lung carcinoma and cultured Lewis lung carcinoma (3LL) cells were from Dr T Sakurai (Keio University, Tokyo, Japan).

Techniques: Incubation, Concentration Assay

Journal: British Journal of Cancer

Article Title: A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors

doi: 10.1038/sj.bjc.6600667

Figure Lengend Snippet: Inhibition of 3LL-cell-induced angiogenesis by KIN-841 as determined using the mouse dorsal air sac method. Dorsal skin of the mice 7 days after implantation of a chamber filled with PBS alone ( A ) or 3LL cells ( B and C ). The implanted mice were treated with 200 mg kg −1 day −1 of KIN-841 for 4 days between days 1 and 6, intraperitoneally ( C ). In ( D ), the grade of angiogenesis induced by 3LL cells is shown using the indexes described in Materials and Methods. a P <0.01 tumour-free controls; b P <0.05 vs tumour controls.

Article Snippet: Lewis lung carcinoma and cultured Lewis lung carcinoma (3LL) cells were from Dr T Sakurai (Keio University, Tokyo, Japan).

Techniques: Inhibition

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: The immunomodulatory effect of TLR agonist and RT was tested in both short term (A) and long term animal studies (B). Experiments were carried out on both C57BL/6 wildtype and cogenic B cell deficient mice. Mice were inoculated with 1×10 5 3LL cells on day 0 and were divided into 5 groups (n = 15/group for wildtype and n = 10/group for B cell deficient mice) that received either no treatment, 20 Gy RT of the primary tumor on day 14 post-tumor inoculation, only control oligo, only TLR9 agonist, or the combination of tumor RT, followed immediately by TLR9 agonist injection on day 14. For short term studies, 25 wildtype or B cell deficient mice were sacrificed on day 15 and splenocytes were harvested for flow cytometry. For long term studies, 75 wildtype and 50 B cell deficient mice were used. TLR9 agonist was injected subcutaneously, twice a week for three weeks (from day 14 to 35). The tumor volume was measured at 1–3-day intervals with a vernier caliper. Of the 75 wildtype mice, 40 mice were sacrificed on day 35 for immunological studies and the remaining 35 mice were used for survival studies. For B cell deficient mice, all of them were sacrificed on day 35 and were used for immunological studies.

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Injection, Flow Cytometry

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: TLR9 agonist induces the proliferation of TLR9-expression splenocytes in mice bearing an ectopic 3LL footpad tumor.

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: C57BL/6 mice bearing 3LL tumor were divided into 5 groups receiving either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist. Splenocytes and sera were harvested 24 hours after treatment. The activation of CD8+ T cells, B cells, pDCs and NKDCs was analyzed by flow cytometry (A) and the release of IFN-γ and IL-10 was analyzed by ELISA (B).

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Activation Assay, Flow Cytometry, Enzyme-linked Immunosorbent Assay

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: Sera from tumor bearing mice treated with either PBS, control oligo, TLR9 agonist, RT (20 Gy) or combined RT and TLR9 agonist were analyzed for the presence of tumor specific antibodies by indirect ELISA coated with total 3LL tumor lysate (A). The total IgG titer was evaluated by an Easy-Titer Mouse IgG Assay Kit (B) and the infiltration of IgG antibody was visualized by confocal microscope after stained with FITC conjugated anti-mouse IgG (C).

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Indirect ELISA, Microscopy, Staining

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: Wild type (C57BL/6) or congenic B cell deficient mice (Igh-6 tm1Cgn ) bearing 3LL tumors were divided into 5 groups receiving either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist. Tumor growth curves were generated by measuring three orthogonal tumor diameters at 1–3-day intervals with a vernier caliper.

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Generated